Comparative Pharmacology
Head-to-head clinical analysis: HUMEGON versus METRODIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMEGON versus METRODIN.
HUMEGON vs METRODIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.
Gonadotropin-releasing hormone (GnRH) agonist; initially stimulates pituitary gonadotropin release, then downregulates GnRH receptors, suppressing LH and FSH secretion.
75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.
750 mg intramuscularly twice weekly for 2-3 weeks; or 500 mg intramuscularly once weekly for 4-6 weeks.
None Documented
None Documented
Terminal half-life approximately 23-24 hours (range 20-30 h) for FSH and LH activity; clinical significance: once-daily dosing achieves steady-state in 4-5 half-lives (approx. 5 days).
Terminal elimination half-life is approximately 35 hours (range 28–48 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Primarily renal (90-95% as intact hormone and metabolites); biliary/fecal excretion minor (<5%).
Primarily renal, with approximately 75% of a dose excreted unchanged in urine within 24 hours; biliary/fecal excretion accounts for less than 5% of elimination.
Category C
Category C
Gonadotropin
Gonadotropin